Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2370786 | 0.84 | CES1 (0.55) | CES1CA1CA2TDP1MAPK1 | |
| SCHEMBL6997964 | 0.80 | CES2 (0.62) | CES1ALDH1A1TSHRCES2LMNA | |
| SCHEMBL22754110 | 0.79 | CES1 (0.63) | CES1CA1CA2TDP1MAPK1 | |
| SCHEMBL10489348 | 0.77 | MAPK1 (0.62) | CES1CA1CA2TDP1MAPK1 | |
| SCHEMBL10354339 | 0.75 | CES2 (0.52) | TDP1MAPK1ALDH1A1TSHRCES2 | |
| SCHEMBL1789385 | 0.74 | RORC (0.51) | MAPK1TSHRLMNAGAAMAPT | |
| SCHEMBL4603989 | 0.73 | CES1 (1.00) | CES1CA1CA2TDP1MAPK1 | |
| SCHEMBL10723714 | 0.73 | SRD5A2 (0.83) | CES1CA1CA2TDP1MAPK1 | |
| SCHEMBL975118 | 0.73 | SRD5A2 (0.83) | CES1CA1CA2TDP1MAPK1 | |
| SCHEMBL10489434 | 0.73 | MAPK1 (0.56) | CES1CA1CA2TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | claimed |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2016-11-24 | — | — | US | disclosed |
| US-9439890-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-09-13 | — | — | US | disclosed |
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2015-10-08 | — | — | US | disclosed |
| US-9096545-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-08-04 | — | — | US | disclosed |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-26 | — | — | US | disclosed |
| EP-0737680-B1 | (Phenylalkylaminoalkyloxyl)-hetero-aryl compounds, processes and intermediates for their preparation and medicaments containing these compounds | SOLVAY PHARM GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6020368-A | MICROBIOCIDES | HINKS JEREMY DAVID (US) | 2000-02-01 | — | — | US | disclosed |
| US-4565648-A | FOR PRODUCTION OF POLYURETHANES | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-21 | — | — | US | disclosed |
| US-4518773-A | \"3-Carbamoyloxy cephalosporins\ | BRISTOL-MYERS COMPANY (US) | 1985-05-21 | — | — | US | disclosed |
| EP-0122449-A1 | Benzoyl ureas | BAYER AG (DE) | 1984-10-24 | — | — | EP | disclosed |
| EP-0103738-A2 | Use of carbonyl compounds and/or heteroanalogous carbonyl compounds as stabilisers for solutions containing pyrocarbonic-acid dialkyl esters, and polyisocyanate preparations containing these compounds | BAYER AG (DE) | 1984-03-28 | — | — | EP | disclosed |
| US-4426520-A | CEPHALOSPORIN ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1984-01-17 | — | — | US | disclosed |
| US-4407755-A | BACTERICIDAL PENICILLINS | BRISTOL-MYERS COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| US-4374982-A | Cepham compounds | BRISTOL-MYERS COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4322347-A | 2-Carbamoyloxymethyl-penicillin derivatives | BRISTOL-MYERS COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4061630-A | 7-Substituted-ureido-3-carbamoyloxymethyl cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGIS, PTGS1 | CES1 291/4885CA1 3662/4885CA2 3726/4885 |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | CES1 148/4885CA1 2987/4885CA2 3208/4885 |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | CES1 148/4885CA1 2987/4885CA2 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.